Overview of Дуглимакс

Property	Description
Active Ingredient	Glibenclamide and Metformin Hydrochloride
Form	Tablet (Fixed-Dose Combination)
Pharmacological Class	Antidiabetic Agent (Sulfonylurea/Biguanide combination)
General Purpose	Improvement of Glycemic Control
Origin	Synthetic

What Type of Medicine is Дуглимакс: Fixed-Dose Combination and Classification

Дуглимакс (Duglimax) is an oral antihyperglycemic agent administered as a fixed-dose combination product for the management of Type 2 Diabetes Mellitus. It is a synthetic medication classified broadly as an Antidiabetic agent, supplied in the tablet dosage form. The combination incorporates two distinct pharmacological classes: a sulfonylurea and a biguanide.

The medication is prescription-only and its formulation reflects the clinically recognized need for complementary pathways in achieving durable glucose reduction. Unlike monotherapies, this preparation delivers the complementary effects of both classes in a single pill, a strategic formulation aimed at improving therapeutic adherence for patients requiring combination therapy.

Composition of Дуглимакс: Glibenclamide and Metformin Hydrochloride

The Дуглимакс tablet composition includes the active ingredients Glibenclamide (a sulfonylurea) and Metformin Hydrochloride (a biguanide). These components function through distinct yet synergistic mechanisms to address the physiological defects of the condition.

Glibenclamide primarily stimulates the pancreas to increase the release of insulin secretion, while Metformin Hydrochloride reduces the amount of glucose produced by the liver and enhances the body's sensitivity to insulin. This dual action ensures the medication addresses both low insulin availability and the body’s resistance to insulin, a key differentiating feature compared to agents that focus solely on either pathway.

General Purpose: Achieving Glycemic Control

The general purpose of Дуглимакс is to achieve and maintain optimal glycemic control by effectively lowering and stabilizing persistently high blood glucose levels in adult patients with Type 2 Diabetes Mellitus. A typical use scenario involves patients whose blood sugar levels are insufficiently managed by diet, exercise, or monotherapy.

The inherent benefit of this fixed-dose combination is the synergy between the components, which provides a more robust antihyperglycemic effect than either agent offers alone. By simultaneously targeting both the release of insulin and the cellular response to it, the drug supports patients with Type 2 Diabetes Mellitus in managing their condition comprehensively, which is fundamental to promoting long-term health.

Regulatory References

Glyburide and Metformin: MedlinePlus Drug Information

What side effects are possible with Дуглимакс?

Possible Side Effects and Safety Information

The official safety documentation for the Glibenclamide/Metformin combination product, Дуглимакс, is structured around the adverse reactions documented for its two active components. The risk profile is dominated by two distinct, serious complications: Lactic Acidosis, which is rare but life-threatening and primarily associated with Metformin, and Severe Hypoglycemia (low blood sugar), which is common and relates to the Glibenclamide component.

Adverse reactions are classified by frequency in regulatory labeling, ranging from Very Common to Very Rare.

Very Common Reactions: These predominantly affect the Gastrointestinal System, including symptoms like diarrhea, nausea, vomiting, abdominal pain, and loss of appetite. These effects are often most prominent at the start of treatment.
Common Reactions: These include Hypoglycemia and Taste Disturbance (metallic taste).
Rare/Very Rare Serious Reactions: These involve Hepatobiliary disorders (hepatitis), Hematological disorders (e.g., agranulocytosis), and Lactic Acidosis.

Regulatory labels specify important safety considerations for certain populations. The drug is contraindicated in patients with severe renal impairment or hepatic failure due to the significantly increased risk of Lactic Acidosis. Older adults generally face a higher risk of severe hypoglycemia and require careful assessment of renal function. Furthermore, the label notes that the medication must be temporarily discontinued before or during iodinated contrast imaging procedures and recommends against alcohol consumption due to increased safety risks.

The regulatory profile documents that certain effects are tied to duration; for instance, Vitamin B12 deficiency is associated with long-term exposure to the Metformin component.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Дуглимакс

Overdose scope

Classification	Detail (Based on Regulatory Labeling)
Documented overdose presentations	Overdose manifestations involve two primary, life-threatening conditions: Hypoglycemia (from Glibenclamide) and Lactic Acidosis (from Metformin).
Physiological systems affected	The label specifies effects on the metabolic system (acidosis, blood glucose) and the central nervous system (confusion, somnolence, coma).
Population-specific overdose notes	The risk and severity of Lactic Acidosis are explicitly increased in patients with impaired renal function due to reduced metformin clearance.

Emergency-response statements

Action Required	When to Seek Urgent Help (Label-Derived Phrasing)
Immediate medical attention is mandatory	If an overdose is suspected or if symptoms of hypoglycemia or lactic acidosis appear. Contact emergency services immediately due to the high mortality rate associated with Lactic Acidosis.

Resulting overdose structure

Official overdose statements:

Overdose may present with symptoms of hypoglycemia (e.g., sweating, confusion, anxiety) or the non-specific signs of lactic acidosis (e.g., malaise, muscle pain, respiratory distress).
Severe outcomes include coma and permanent neurological damage from hypoglycemia, and the life-threatening metabolic emergency of lactic acidosis.
Treatment for severe hypoglycemia requires the administration of intravenous glucose. For severe lactic acidosis, hemodialysis is the documented procedural measure required for compound removal and acidosis correction.
Continuous hospital monitoring is required for all patients with suspected overdose.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents define the overdose profile by the two distinct, severe metabolic emergencies derived from its components. Consequently, the official emergency-seeking conditions require that immediate medical care and hospital monitoring be sought for any suspected overdose, specifying supportive procedural steps such as intravenous glucose or hemodialysis as documented interventions. The regulatory framework highlights the critical need for rapid professional response and specialized hospital-level observation to manage these documented manifestations.

Therapeutic Uses of Дуглимакс

What Дуглимакс Treats: Main Uses and Benefits

The primary role of Дуглимакс (Glibenclamide/Metformin) is to provide support for managing Type 2 Diabetes Mellitus (T2DM) in adults. This medication is generally applied in clinical settings where patients' blood glucose levels are insufficiently managed despite following diet, exercise, and the use of a single oral agent (monotherapy). The combination generally helps improve blood sugar management for adults with Type 2 Diabetes, as part of a therapeutic plan that includes diet and exercise.

Stabilizing Chronic High Blood Glucose

Дуглимакс is relevant for managing the symptom cluster of persistent hyperglycemia, which involves reducing high blood sugar readings both when fasting and after meals. It is used for managing the chronically elevated glucose levels that characterize uncontrolled T2DM, which may assist with easing symptoms related to noticeable physiological strain. Maintaining stable blood glucose levels supports patients during symptomatic phases and may be part of managing the potential for long-term health issues associated with chronic high blood sugar.

Supporting Adherence to Combination Therapy

The formulation is used in scenarios where additional management of discomfort is required by simplifying the treatment regimen for adult patients who need two distinct anti-diabetic agents. The use of a single tablet generally supports patients in maintaining adherence, which may contribute to more consistent therapeutic support.

Quick Fact: Relief for Persistent Hyperglycemia The medication is applied to address the symptom cluster of persistent hyperglycemia, supporting general well-being during symptomatic phases.

Eligibility and Restrictions for Use

This section explains the official population eligibility and exclusions for Дуглимакс (Glibenclamide and Metformin) as defined in regulatory documents.

Eligibility and Exclusion Status

Classification	Eligibility Rule (Official Basis)
Populations Allowed	Adults (18 years and older) with Type 2 Diabetes Mellitus are the indicated population.
Populations Contraindicated	Severe renal impairment (eGFR < 30 mL/min/1.73 m^2); hepatic insufficiency; any form of acute metabolic acidosis (e.g., lactic acidosis, diabetic ketoacidosis); Type 1 Diabetes Mellitus; pregnancy; and breastfeeding [Source 1.1, 2.7].
Restricted/Conditional Use	Older adults require frequent renal function monitoring and should not be titrated to maximum doses [Source 1.1]. Initiation is not recommended if eGFR is between 30 and 44 mL/min/1.73 m^2 [Source 1.6].
Age Restriction	Pediatric patients (under 18 years): Safety and effectiveness have not been established [Source 1.5, 2.6].

Official regulatory labeling strictly prohibits the use of this medicine in the presence of severe organ dysfunction or acute metabolic instability, as these conditions significantly increase the risk of serious complications. The authorized use is explicitly limited to adults with Type 2 Diabetes Mellitus, reflecting official data on safety and efficacy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for the Glibenclamide/Metformin fixed-dose combination.

Contraindicated Combinations

Co-administration with Miconazole (systemic oromucosal gel) is formally prohibited, as regulatory labels state it significantly potentiates the hypoglycaemic effect of Glibenclamide. Co-administration with Bosentan is also contraindicated due to a documented increase in the risk of elevated liver enzymes.

Interaction Restrictions

Constraint Type	Interacting Substance/Class	Official Regulatory Statement
Prohibition/Timing	Iodinated Contrast Agents	Requires temporary discontinuation prior to or at the time of the procedure due to the documented risk of Metformin accumulation and lactic acidosis.
Exposure Risk	Cationic Drugs (e.g., Cimetidine, Ranolazine)	These substances are documented to increase Metformin accumulation by competing for renal tubular transport systems, which elevates the risk of lactic acidosis.
Metabolic Impact	CYP 2C9 Inhibitors	Documented to reduce Glibenclamide clearance, officially leading to a potentiation of the blood glucose-lowering effect.
Food/Substance	Alcohol (Ethanol)	Officially documented to potentiate the effect of Metformin on lactate metabolism, reinforcing the risk of lactic acidosis.
PD Interference	Hyperglycemia-Inducing Agents (e.g., Glucocorticoids, Thiazides)	Documented to cause a loss of blood glucose control due to counteractive pharmacodynamic effects.

Administration Requirements

Administration of Colesevelam must be separated from this product to mitigate the documented reduction in Glibenclamide absorption. Furthermore, regulatory labels note that the Alcohol-related interaction is of greater significance in patients with Hepatic Insufficiency.

Mechanism of Action

How Дуглимакс Works: Mechanism of Action

Stimulation of Endogenous Insulin Secretion

The Glibenclamide component acts as an insulin secretagogue by directly targeting the pancreatic beta-cells. Its mechanism initiates when it binds to and blocks the Sulfonylurea Receptor 1 ( SUR1), a subunit of the ATP-sensitive potassium channel ( K ATP channel). This molecular blockade induces cell membrane depolarization, which triggers the opening of voltage-dependent calcium channels and subsequent Ca^2+ influx. The resulting physiological effect is the forced release of pre-formed insulin from the pancreas, thereby increasing the circulating concentration of the primary metabolic hormone, which facilitates glucose clearance.

Suppression of Hepatic Glucose Production

The complementary Metformin component accumulates in the liver where it acts by inhibiting the Mitochondrial Respiratory Chain Complex I. This process perturbs the cellular energy balance, leading to the activation of the metabolic sensor AMP-activated protein kinase ( AMPK). AMPK activation then suppresses the gene expression of key enzymes responsible for gluconeogenesis. The core physiological consequence is a reduction in the liver's release of new glucose into the bloodstream and increased insulin responsiveness in peripheral tissues.

Dosage and Administration Information

How to Use Дуглимакс: Administration Guidelines

Дуглимакс (Glibenclamide/Metformin fixed-dose combination) is an oral medication utilized for the long-term management of Type 2 Diabetes Mellitus. Its proper use is defined by specific instructions regarding dose, schedule, and patient monitoring, as outlined in prescribing information.

Administration Scope and Dosing

Feature	Instruction
Route of Administration	The medicine is administered via the oral route using a fixed-dose tablet
Dosing Schedule	Initial therapy typically begins with the lowest available strength (1.25 mg / 250 mg) taken once or twice daily. The dose is then gradually titrated (adjusted) by the healthcare provider at intervals not less than two weeks to establish the appropriate maintenance dose.
Maximum Daily Dose	The maximum permissible intake is 20 mg Glibenclamide / 2000 mg Metformin per day

Frequency and Contextual Requirements

Feature	Administration Guideline
Timing in Relation to Meals	Дуглимакс must be taken with meals, typically in divided doses (twice daily), to promote better tolerance
Special Procedural Conditions	Assessment of estimated Glomerular Filtration Rate (eGFR) is mandatory prior to starting treatment and requires regular monitoring throughout therapy. The medicine must be temporarily discontinued before or at the time of intravascular iodinated contrast imaging procedures in certain patients and only reinstituted once renal function is confirmed as stable or normal
Missed-Dose Rule	If a dose is missed, the patient should not take a double dose; the next dose should be taken at the usual scheduled time
Older Adults	Dosing for older adults must be conservative and initiated at the lowest possible strength, consistent with the need for vigilant renal function checks

The use protocol establishes a structured, chronic administration regimen defined by fixed meal timing and a required titration phase. This framework ensures consistent administration aligned with established guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Дуглимакс

The body of research for the fixed-dose combination of glibenclamide and metformin, marketed as Дуглимакс, primarily consists of controlled clinical trials and real-world observational studies. This evidence base was established to explore how the combination is associated with blood sugar measurements across different patient scenarios. The research monitors specific physiological changes and patient-related factors, remaining a non-advisory, patient-friendly research overview.

Research Evidence for Initial Management of Type 2 Diabetes

Initial research exploring the combination involved Randomized Controlled Trials ( RCTs) that compared the fixed-dose product against its two active ingredients given alone (monotherapy). These studies primarily focused on adults with newly identified Type 2 Diabetes. The primary metrics of interest were measurements of blood sugar biomarkers like Glycated Hemoglobin ( HbA1c), Fasting Plasma Glucose ( FPG), and Post-Prandial Glucose ( PPG). Findings from these short-to-medium-term studies described the patterns of HbA1c measurements across the different treatment groups.

Research for Patients with Sub-Optimal Blood Sugar Control

Comparative RCTs and systematic reviews were used in research examining patients whose blood sugar control was sub-optimal despite treatment with a single drug (either metformin or a sulfonylurea). The research monitored the differences in glycemic marker values ( HbA1c, FPG) at defined intervals during the study period, following the switch to the combination product. Studies reported the measured differences in blood sugar biomarker values when the combination was compared to groups that continued on a single agent.

Long-Term Outcomes, Follow-up, and Durability of Observations

The research exploring the patterns associated with the combination components on long-term health outcomes relied primarily on retrospective observational cohort studies and predictive computer modeling, as dedicated, long-duration RCTs are rare. The studies tracked or projected the incidence of major adverse cardiovascular events ( MACE), including hospitalization for stroke, heart failure, and acute myocardial infarction. The certainty regarding the long-term patient-level outcomes remains low to moderate, as the findings are largely derived from observational data and predictive projections, which introduce inherent uncertainty.

Evidence Gaps and Areas of Research Uncertainty

The overall evidence for Дуглимакс is predominantly derived from short-term trials (less than one year), meaning that the certainty of long-term patient-level outcomes is not fully established. Comparative evidence is lacking regarding the fixed-dose combination versus newer, alternative classes of anti-diabetic medications that have since become available. Furthermore, the results apply only to the populations studied, and there is limited information available for some patient groups, such as children and adolescents with Type 2 Diabetes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Дуглимакс (FAQ)

Q: Is Дуглимакс the same type of medicine as [similar drug name]? How is it different?

Official product information classifies this medicine as a fixed-dose combination of two distinct pharmacological classes: a sulfonylurea and a biguanide. This formulation delivers a dual mechanism of action, which addresses two different issues in Type 2 Diabetes management. The medicine works by both stimulating insulin release and reducing the amount of glucose produced by the liver.

Q: Is it true that Дуглимакс has been studied in people with [specific condition]?

Regulatory documents specify that this medicine is indicated only for the management of Type 2 Diabetes Mellitus in adults when used according to approved conditions. Its approved use, according to regulatory information, is specifically defined for adults with Type 2 Diabetes Mellitus.

Q: Are there any widely known products or foods that should be avoided while using Дуглимакс?

Official warnings document the potential risk associated with consuming alcohol (ethanol), as regulatory information indicates it may increase the risk of a serious complication called lactic acidosis. The official label also details specific restrictions for certain drug and substance combinations that have documented interaction risks.

Q: Why is it necessary to take Дуглимакс exactly as described?

Following the administration guidelines, as defined in the official label, supports both patient tolerance and treatment safety. Regulatory documents specify that taking the dose with meals is intended to promote better tolerance, and rules for temporary discontinuation are set to help prevent the documented risk of complications.

Q: How does Дуглимакс fit into the overall treatment plan for [condition it treats]?

This medicine is officially indicated for use as an adjunct to diet and exercise for adult patients. It is typically considered when blood sugar control is not achieved by these initial measures or by using a single medicine (monotherapy).

Q: What is the expected long-term experience with Дуглимакс?

Regulatory labels outline that the long-term use of the Metformin component is associated with a potential risk of Vitamin B12 deficiency, which requires monitoring. Official protocols involve the periodic monitoring of kidney function and blood parameters throughout the course of treatment.

Q: Does Дуглимакс interact with common pain relievers like [NSAID example]?

The regulatory label documents warnings for several drug classes that can affect kidney function or blood glucose levels. The specific potential for interaction relies on the individual pain reliever or medication, as regulatory information lists various classes of interacting substances.

Q: Why are people often prescribed Дуглимакс instead of other similar drugs?

The medicine is a fixed-dose combination designed to provide a synergistic or combined effect. According to official mechanism descriptions, it targets two distinct physiological issues: it stimulates insulin release and simultaneously reduces glucose production in the liver, which is designed to support more comprehensive glycemic control.

Q: Is Дуглимакс a cure for [condition it treats]?

No. Official documents explicitly state that the medicine is utilized for the long-term management of Type 2 Diabetes Mellitus. The effect is required continuously to help stabilize persistently high blood glucose levels.

Q: How is Дуглимакс different from older treatments for this condition?

This medicine is classified as a fixed-dose combination that includes a second-generation sulfonylurea and a biguanide. Its pharmacological makeup and dual mechanism of action define its difference relative to other single-agent treatments for the condition.

Q: What does the research say about the long-term safety of Дуглимакс?

Official safety information specifies that long-term use requires periodic monitoring for potential issues such as Vitamin B12 deficiency. Regulatory protocols define the need for ongoing monitoring of kidney function and blood parameters.

Q: Is Дуглимакс considered a high-risk medication?

The regulatory label documents the potential for serious complications, which defines its risk profile. This includes the rare but life-threatening risk of Lactic Acidosis associated with the Metformin component and the common risk of Severe Hypoglycemia (low blood sugar) from the Glibenclamide component.

Q: What official warnings or boxed warnings are associated with Дуглимакс?

Regulatory documents feature specific, formalized safety warnings. The most notable of these, often highlighted in a Boxed Warning format, concerns the risk of Lactic Acidosis, especially in patients with impaired kidney function.

Q: What is the typical duration of treatment with Дуглимакс?

Official documentation specifies that the medicine is utilized for the long-term management of Type 2 Diabetes Mellitus. The condition is chronic, meaning the use of the medicine is generally ongoing to maintain blood glucose stability.

Q: How long does it typically take to see the expected effects of Дуглимакс?

The official administration protocol includes a titration phase for dose adjustment. This process involves the healthcare provider gradually adjusting the dosage over a defined time period to find the appropriate maintenance dose.

Q: Can I take Дуглимакс if I am currently using vitamins or supplements?

The regulatory label notes that the long-term use of the Metformin component is associated with a potential for Vitamin B12 deficiency. Because of this documented effect, official regulatory protocols include considerations for monitoring B12 status.

Q: What happens if I stop taking Дуглимакс suddenly?

Since the medicine is prescribed for the long-term control of high blood sugar, stopping it would be expected to reverse the blood glucose-lowering effects. This could potentially result in a loss of glycemic control over time.

Q: Does Дуглимакс require a special diet or lifestyle change?

Yes. Official regulatory documents indicate that the medicine is to be used as an adjunct to diet and exercise. Maintaining these measures is considered a required condition of use alongside the medication.

Q: Is Дуглимакс used for anything besides its main listed purpose?

Regulatory documents state the medicine's single official purpose is the management of Type 2 Diabetes Mellitus in adults. No other uses are officially indicated or approved by health authorities.

Q: Is it normal to feel tired when first starting Дуглимакс?

The regulatory label lists hypoglycemia (low blood sugar) as a common side effect of the Glibenclamide component. Feelings of tiredness or fatigue are known symptoms that may be experienced when blood sugar levels drop too low.

Q: Is there a generic version of Дуглимакс available?

Yes, regulatory registries in many countries list therapeutically equivalent generic options for the Glibenclamide and Metformin fixed-dose combination. These alternatives contain the same active ingredients and are approved as therapeutically equivalent.

Q: Can Дуглимакс cause changes in mood or behavior?

The regulatory label lists hypoglycemia (low blood sugar) as a common side effect. Symptoms of severe hypoglycemia can potentially include mental changes such as confusion or changes in behavior.

Q: Is the effect of Дуглимакс permanent, or does it only last while I am taking it?

The medicine is explicitly designated for the long-term management of Type 2 Diabetes Mellitus, meaning the effects are not permanent and generally only last while the medicine is being taken.

Q: Is it possible to become dependent on Дуглимакс?

Regulatory documents do not classify this medicine as a controlled substance and contain no warnings or information regarding dependence or abuse potential.

Q: What documentation or official sources describe the use of Дуглимакс?

The definitive source of information is the official Prescribing Information (also known as the regulatory label or Summary of Product Characteristics). This document is approved and maintained by governmental health authorities.

Q: Do I need to change my activities while taking Дуглимакс, such as driving?

The regulatory label includes warnings regarding the risk of hypoglycemia (low blood sugar). Because low blood sugar may impair mental alertness, regulatory warnings caution about performing tasks requiring focus, such as driving or operating machinery.

Q: Are headaches a commonly reported side effect of Дуглимакс?

Headaches are not listed as a very common or common adverse reaction on their own. However, official safety documentation notes that headaches can be a symptom experienced during an episode of hypoglycemia (low blood sugar), which is a common side effect of the medicine.

Q: Can Дуглимакс be used if I have allergies to other medicines?

Official prescribing information explicitly contraindicates the use of this medicine in patients with a known hypersensitivity to Glibenclamide, Metformin, or any component of the formulation.

Q: Can Дуглимакс cause weight changes?

Official documents for the components list weight-related changes as potential adverse reactions. The weight effect can vary because the medicine combines two different components with differing effects on body weight.

Q: What if my symptoms seem worse after starting Дуглимакс?

The use of this medicine requires periodic monitoring of blood glucose and HbA1c to ensure that the treatment is effective in lowering high blood sugar. If blood glucose control appears suboptimal, official regulatory protocols define the need for professional evaluation.

How should Дуглимакс be stored and disposed of?

How to Store and Dispose of Duglimax (Glibenclamide and Metformin HCl)

Storage of Duglimax tablets must follow specific regulatory requirements to maintain product integrity and safety. The medication must be kept at controlled room temperature, typically 68 F to 77 F (20 C to 25 C), and should not be frozen. Tablets must be protected from light, moisture, and excess heat, and stored in their original, tightly closed container.

To ensure safety, always keep this medicine out of the reach of children. Do not use the tablets past the expiration date printed on the package.

For disposal, the preferred method is an authorized drug take-back program. The product should not be flushed down the toilet. If a take-back program is unavailable, unused tablets can be mixed with an unappealing substance (like coffee grounds) and placed in a sealed bag before being thrown in the household trash.

Дуглимакс